Luger S M, Ratajczak J, Ratajczak M Z, Kuczynski W I, DiPaola R S, Ngo W, Clevenger C V, Gewirtz A M
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Blood. 1996 Feb 15;87(4):1326-34.
The Vav protooncogene is expressed almost exclusively in hematopoietic cells, but its role in regulating adult human hematopoietic cell development remains uncertain. To analyze Vav function in adult blood cell formation, we used antisense (AS) oligodeoxynucleotides (ODN) to disrupt its expression in normal and malignant human hematopoietic cells. Bone marrow or peripheral blood mononuclear cells (MNC) were obtained from consenting normal donors and patients with acute or chronic myelogenous leukemia (AML and CML, respectively) and polycythemia vera (PV). Adherent and T-cell-depleted (A-T-) MNC or CD34+ MNC were exposed to unmodified sense, antisense, or scrambled sequence ODN corresponding to codons 2-7 of Vav's mRNA sequence. Cells were then assayed for Vav mRNA expression by reverse transcription-polymerase chain reaction and Vav protein expression by Western binding. After showing that Vav-targeted AS ODN could specifically diminish Vav mRNA and protein expression, we assessed the ability of Vav-deficient cells to form myeloid and erythroid colonies in methyl-cellulose cultures. When normal CD34+ MNC were exposed to Vav AS ODN, no effect on colony-forming unit-granulocyte-macrophage (CFU-GM) or CFU-megakaryocyte colony formation was observed. In contrast erythroid colony growth was inhibited by a mean +/- SD of 62% +/- 16%. In patients with hematopoietic malignancies. Vav-targeted AS ODN inhibited CFU-GM colony formation in a sequence-specific and dose-dependent manner in 1 of 3 AML, 13 of 17 CML, and 2 of 2 PV patients. At the highest concentration used, the Vav AS ODN inhibited CFU-GM colony formation from 66% to 81% when compared with control cell colony growth. Burst-forming unit-erythroid (BFU-E) colony-formation was also assessed in 7 PV patients. The Vav-targeted AS ODN inhibited BFU-E colony formation in all by a mean +/- SD of 81% +/- 4%. These findings suggest that Vav function may not be easily complemented in a significant subset of normal adult erythroid progenitor cells and may also be necessary for myeloid progenitor cell growth in a variety of hematopoietic malignancies.
Vav原癌基因几乎只在造血细胞中表达,但其在调节成体人类造血细胞发育中的作用仍不明确。为了分析Vav在成体血细胞形成中的功能,我们使用反义(AS)寡脱氧核苷酸(ODN)来破坏其在正常和恶性人类造血细胞中的表达。从同意参与的正常供体以及急性或慢性髓性白血病(分别为AML和CML)和真性红细胞增多症(PV)患者中获取骨髓或外周血单个核细胞(MNC)。将贴壁且去除T细胞的(A-T-)MNC或CD34+ MNC暴露于与Vav mRNA序列的2至7密码子相对应的未修饰的正义、反义或随机序列ODN。然后通过逆转录 - 聚合酶链反应检测细胞的Vav mRNA表达,并通过蛋白质免疫印迹检测Vav蛋白表达。在证实靶向Vav的AS ODN可特异性降低Vav mRNA和蛋白表达后,我们评估了Vav缺陷细胞在甲基纤维素培养基中形成髓系和红系集落的能力。当正常CD34+ MNC暴露于Vav AS ODN时,未观察到对粒 - 巨噬细胞集落形成单位(CFU - GM)或巨核细胞集落形成的影响。相反,红系集落生长受到抑制,平均抑制率为62%±16%。在造血系统恶性肿瘤患者中,靶向Vav的AS ODN以序列特异性和剂量依赖性方式抑制了3例AML患者中的1例、17例CML患者中的13例以及2例PV患者中的2例的CFU - GM集落形成。在所使用的最高浓度下,与对照细胞集落生长相比,Vav AS ODN将CFU - GM集落形成抑制了66%至81%。还对7例PV患者评估了红系爆式集落形成单位(BFU - E)集落形成。靶向Vav的AS ODN在所有患者中均抑制了BFU - E集落形成,平均抑制率为81%±4%。这些发现表明,Vav功能在相当一部分正常成体红系祖细胞中可能不易被代偿,并且在多种造血系统恶性肿瘤中的髓系祖细胞生长中可能也是必需的。